Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN 3: Semaglutide vs Exenatide ER in Type 2 Diabetes
NCT01885208Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2013
- Primary completion
- Jul 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01885208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01885208.